1. Anderson, S.C., Johnson, D.E., Harris, M.P., Engler, H., Hancock, W., Huang, W.M., Wills, K.N., Gregory, R.J., Sutjipto, S., Wen, S.F., Lofgren, S., Shepard, H.M., and Maneval, D.C., 1998. P53 gene therapy in a rat model of hepatocellular carcinoma:intra-arterial delivery of a recombinant adenovirus. Clin. Cancer. Res.7:1649–1659.
2. Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., and Finberg, R.W. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science275:1320–1323.
3. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M, Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., and McCormick F, 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373–376.
4. Clary, B.M., and Lyerly, H.K., 1998. Transcriptional targeting for cancer gene therapy. Surg. Oncol. Clin. N. Am.7:565–574.
5. Connelly, S., Andrews, J.L., Gallo, A.M., Kayda, D.B., Qian, J., Hoyer, L., Kadan, M.J., Gorziglia, M.I., Trapnell, B.C., McClelland, A., and Kaleko, M., 1998. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood.91:3273–3281.